NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Countries: Spain

The aim of the ORESTES study is to describe the characteristics of the COPD patients initiating Trixeo (BGF -budesonide/glycopyrronium/formoterol) in Spain and to assess their real-world outcomes up to 12 months afterwards. For that purpose,a descriptive, observational, multi-centre, longitudinal, retrospective cohort study involving \~20 Spanish centres and aiming to include between 500 and 700 patients, has been designed.

Eligibility overview

Sex: ALL

Age: 40 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1 .Patient diagnosed with COPD confirmed by spirometry (postbronchodilator FEV1/FVC\<0.7).

2\. Patients treated with BGF initiated at least 12 months before start of data collection.

3\. Patients with information available at least 12 months before BGF initiation.

4\. Adult patients aged ≥40 years old at index date.

Exclusion Criteria:

1. Subjects with BGF treatment not intended for COPD (e.g., intended for asthma).
2. Subject participated in a clinical trial during the study data observation period.

Locations (15)

Barcelona, Spain
Granada, Spain
Lleida, Spain
Lugo, Spain
Madrid, Spain
Málaga, Spain
Murcia, Spain
Ourense, Spain
Oviedo, Spain
Palma de Mallorca, Spain
Santa Cruz de Tenerife, Spain
Seville, Spain
Valencia, Spain
Vitoria-Gasteiz, Spain
Zaragoza, Spain